Clinical Trial Update: A Safety and Efficacy Study of DENSPM in Patients With Liver Cancer Who Are Not Eligible for Surgical Care [Phase 1, Phase 2]

View source ↗

Summary

The DENSPM trial in hepatocellular carcinoma patients not eligible for surgical care (Phase 1/2) was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• DENSPM (N1,N11-diethylnorspermine)

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Carcinoma, Hepatocellular | Phase 1, Phase 2 | Status: TERMINATED